Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yongwei Chen

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Journal of the American Chemical Society|January 31, 2024
Tailoring Hydrophobicity and Pore Environment in Physisorbents for Improved Carbon Dioxide Capture under High HumidityXiaoliang Wang, Maytham Alzayer, Arthur J Shih, et al.
NPJ Digital Medicine|October 7, 2024
Screening chronic kidney disease through deep learning utilizing ultra-wide-field fundus imagesXinyu Zhao, Xingwang Gu, Lihui Meng, et al.
Bioscience Trends|December 25, 2024
Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)Haowen Tang, Wenwen Zhang, Junning Cao, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Journal of the American Chemical Society|January 31, 2024
Tailoring Hydrophobicity and Pore Environment in Physisorbents for Improved Carbon Dioxide Capture under High HumidityXiaoliang Wang, Maytham Alzayer, Arthur J Shih, et al.
NPJ Digital Medicine|October 7, 2024
Screening chronic kidney disease through deep learning utilizing ultra-wide-field fundus imagesXinyu Zhao, Xingwang Gu, Lihui Meng, et al.
Bioscience Trends|December 25, 2024
Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)Haowen Tang, Wenwen Zhang, Junning Cao, et al.
Pageof 8